Amended Securities Registration (section 12(g)) (8-a12g/a)
November 14 2012 - 8:56AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-A/A
(Amendment No. 1)
FOR REGISTRATION OF CERTAIN CLASSES OF
SECURITIES
PURSUANT TO SECTION 12(b) OR 12(g) OF
THE
SECURITIES EXCHANGE ACT OF 1934
NORTHWEST BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in
its Charter)
Delaware
|
0-33393
|
94-3306718
|
(State or Other Jurisdiction of
|
(Commission File Number)
|
(IRS Employer
|
Incorporation or Organization)
|
|
Identification No.)
|
4800 Montgomery Lane, Suite
800, Bethesda, MD 20814
(Address of principal
executive offices) (Zip Code)
Securities to be registered pursuant to Section
12(b) of the Act:
Title of
each class to be registered: Common Stock, par value $0.001 per share
Name of each exchange on which each class
is to be registered: The NASDAQ Stock Market LLC
If this Form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), please check the following box.
x
|
|
If this Form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), please check the following box.
¨
|
Securities Act registration statement file
number to which this form relates: 333-182470
Securities to be registered pursuant to Section
12(g) of the Act: None.
Item 1. Description
of Registrant's Securities to be Registered.
The description of the common stock of Northwest
Biotherapeutics, Inc. (the “Registrant”), as included under the caption “Description of Securities” in
the prospectus forming a part of the Registration Statement on Form S-1, as amended (Registration No. 333-182470) (the
“Registration Statement”), filed under the Securities Act of 1933, as amended (the “Securities Act”), is
incorporated by reference herein. In addition, any description of such securities contained in a form of prospectus relating to
the Registration Statement subsequently filed by the Company pursuant to Rule 424(b) under the Securities Act shall be deemed to
be incorporated by reference herein.
Item 2. Exhibits.
Under the Instructions as to Exhibits with
respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The NASDAQ
Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities
Exchange Act of 1934, as amended.
SIGNATURE
Pursuant to the requirements
of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on
its behalf by the undersigned, thereto duly authorized.
|
NORTHWEST BIOTHERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: November 14, 2012
|
By:
|
/s/ Linda Powers
|
|
|
|
Name: Linda Powers
|
|
|
|
Title: Chief Executive Officer
|
|
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Oct 2023 to Oct 2024